研究单位：[1]Pfizer[2]Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China, 430030[3]Nanfang Hospital, Southern Medical University Guangzhou, Guangdong, China, 510515[4]The Affiliated Hospital of Guizhou Medical University Guiyang, Guizhou, China, 550004[5]Henan Provincial People's Hospital Zhengzhou, Henan, China, 450003[6]Xiangya Hospital of Centre-South University Changsha, Hunan, China, 410008[7]Department of Hematology,The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China, 215006[8]Department of Hematology,The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China, 221006[9]Department of Hematology,Jiangxi Provincial People's Hospital Nanchang, Jiangxi, China, 330006[10]Blood Center of Shandong Province Jinan, Shandong, China, 250014[11]Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine/Hematology Department Shanghai, Shanghai, China, 200025[12]Shanxi Medical University Second Hospital Taiyuan, Shanxi, China, 030001[13]Chengdu Women's and Children's Central Hospital Chengdu, Sichuan, China, 610073[14]Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology) Tianjin, Tianjin, China, 300020[15]Department of Hematology,The First Affiliated Hospital of Kunming Medical University Kunming, Yunnan, China, 650032[16]Hematology Department,Beijing Children's Hospital, Capital Medical University Beijing, China, 100045[17]Children's Hospital of Chongqing Medical University Chongqing, China, 400014
研究目的：
The purpose of this post-approval study is to evaluate the safety and efficacy of Benefix in subjects with hemophilia B in usual care settings in China.
